Psoriatic Arthritis
Conditions
Keywords
Ultrasound, Psoriatic arthritis, Outcome measures, Apremilast, Disease activity
Brief summary
The main purpose of this study is to validate the ultrasound scores PsASon22 and PsASon13 in patients with active psoriatic arthritis undergoing a treatment with Apremilast.
Detailed description
This is a prospective, multicentre, phase IV trial assessing the value of the ultrasound scores PsASon22 and PsASon13 in differentiating between clinically active and inactive patients with psoriatic arthritis, following a treatment with Apremilast for up to 24 months. Additionally, convergent construct validity, inter/intra-reader reliability, sensitivity to change and differences in change in certain patients will be tested for the ultrasound scores.
Interventions
DRUGApremilast
Single arm receiving Apremilast and ultrasound examinations
Sponsors
Celgene Corporation
Medical University of Vienna
Medical University Innsbruck
Medical University of Graz
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
1. Male or female patient ≥18 years and \<90 years of age 2. PsA according to CASPAR criteria 3. Peripheral manifestation (arthritis, tenosynovitis, dactylitis and/or enthesitis) 4. Active disease as defined by a DAPSA \>14 and clinical indication for treatment with Apremilast (as per approved indication for PsA, including failure to methotrexate) 5. Written informed consent
Exclusion criteria
1. Inability to perform US at any site included in the PsASon22 or PsASon13 score (f.e. due to complete destruction of a joint) 2. Planned surgery within the study period or history of surgery of any of the joints to be investigated clinically or by sonography. 3. Contraindication to Apremilast (as per patient information leaflet) 4. Current severe medical illness requiring hospitalization 5. Pregnancy or lactation 6. Inability of the patient to follow the treatment protocol 7. Fulfillment of the MDA Criteria or DAPSA≤14 8. Current treatment with any investigational drug 9. Current treatment with glucocorticoids at a prednisone equivalent \>10mg 10. Intra-articular glucocorticoid injection in one of the joints to be investigated clinically or by sonography, or intra-muscular glucocorticoid injection within 8 weeks before baseline 11. Change, including dosage changes or discontinuation, of csDMARD treatment (with the exception of leflunomide) in the last 4 weeks before baseline 12. Change, including dosage changes or discontinuation of leflunomide treatment in the last 8 weeks before baseline. (Exception: If patients stop leflunomide and complete an 11 day treatment with cholestyramine (8g, 3 x daily), prior to the baseline visit, they may enter the study.) 13. Current bDMARD, tsDMARD treatment 14. Prior bDMARD or tsDMARD treatment without a minimal washout period before baseline (the minimal washout period is twice the half-life of the respective drug)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The difference in the change-score of the PsASon22 | 4-12-24 months | The main outcome is the difference in the change-score of the PsASon22 between patients achieving low disease activity or remission (DAPSA≤14) and patients not achieving this target under a treatment with Apremilast. The Psoratic Arthritis Sonography Score 22, PsASon22 (range 0-260), is a sum score, including grey scale and power doppler measurements of 22 joints (6 MCPs, 4-H-PIPs, 2 MTPs, 4 H-DIPs, 2 F-DIPs, 4 large joints) and 4 entheses (lateral epicondyle and distal patella - bilateral), with a higher score presumably indicating higher disease activity. |
| The difference in the change-score of the PsASon13 | 4-12-24 months | The main outcome is the difference in the change-score of the PsASon13 between patients achieving low disease activity or remission (DAPSA≤14) and patients not achieving this target under a treatment with Apremilast. The Psoratic Arthritis Sonography Score 13, PsASon13 (range 0-134), is a sum score, including grey scale and power doppler measurements of 13 joints (2 MCPs, 3-H-PIPs, 1-F-PIP, 2 MTPs, 1 H-DIPs, 2 F-DIPs, 2 large joints) and 2 entheses (lateral epicondyle and distal patella - unilateral), with a higher score presumably indicating higher disease activity. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Interrater reliability of PsASon22 and PsASon13 | 4-12-24 months | Interrater reliability will be assessed by performing multiple ultrasound examinations for one patient by multiple examinators |
| Convergent construct validity of PsAson22 and PsASon13 | 4-12-24 months | Convergent construct validity will be assessed by correlating the ultrasound scores to clinical composite scores (f.e. DAPSA) |
| Differences in PsASon22 and PsASon13 change | 4-12-24 months | Differences in change will be assessed by comparing the change scores of patients with initially high disease activity (DAPSA\>28) with the change scores of patients with initially moderate disease activity (DAPSA\>14-≤28) |
| Intrarater reliability of PsASon22 and PsASon13 | 4-12-24 months | Intrarater reliability will be assessed by performing multiple ultrasound examinations for one patient by multiple examinators |
| Sensitivity to Change of PsASon22 and PsASon13 | 4-12-24 months | Sensitivity to change will be assessed by measuring the PsASon22 and PsASon 13 scores at four different time points (Baseline and after 4, 12 and 24 months) |
Countries
Austria
Outcome results
None listed